Related Experiment Videos

Impact of calcium antagonists on bleeding time in patients with chronic renal failure

K Hayashi1, H Matsuda, M Honda

  • 1Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan. khayashi@mc.med.keio.ac.jp

Insights

Calcium antagonists prolong bleeding time in patients with chronic renal failure. However, this laboratory finding does not typically lead to significant bleeding events.

Area of Science:

  • Nephrology
  • Hematology
  • Pharmacology

Background:

  • Chronic renal failure (CRF) is associated with hemorrhagic diathesis.
  • Calcium antagonists are commonly prescribed antihypertensives in CRF patients.
  • The effect of calcium antagonists on bleeding time in CRF is not well-established.

Purpose of the Study:

  • To investigate whether calcium antagonists influence bleeding time in patients with chronic renal failure.
  • To correlate bleeding time with renal function parameters and platelet counts.

Main Methods:

  • A cohort of 156 patients with CRF was studied.
  • Bleeding time was measured using Ivy's method.
  • Blood parameters including BUN, creatinine, platelet count, and hemoglobin were analyzed.

Main Results:

  • Patients taking calcium antagonists showed a significantly higher incidence of prolonged bleeding time (31/122) compared to those not taking them (3/34).
  • A positive correlation was found between bleeding time and BUN in both groups.
  • Odds ratio for prolonged bleeding time was 3.52 in patients on calcium antagonists.
  • Withdrawal of calcium antagonists shortened bleeding time in treated patients.

Conclusions:

  • Calcium antagonists prolong bleeding time in patients with chronic renal failure.
  • This subclinical prolongation of bleeding time is not necessarily associated with clinically significant hemorrhagic events.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...